Session Information
Date: Thursday, June 23, 2016
Session Title: Dystonia
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: The aim of this paper was to analyze efficacy and safety of abobotulinumtoxinA (A/Abo), and compare them between the groups of patients with CD and HFS.
Background: Treatment of craniocervical dystonia (CD) and hemifacial spasm (HFS) with botulinum neurotoxin A is efficient in around 70% of the patients. However, side effects may occur in 20 to 25%, but as a rule are mild and transient.
Methods: A total of 86 patients treated with A/Abo (Dysport®) were analyzed (63 women, 60.63±11.84 years of age, duration of disease 10.38±10.55 years, duration of treatment 3.91±2.98 years), of whom 50 with CD (37 women, age 58.52±12.43 years) and 36 with HFS (26 women, age 63.58±10.43 years). A specially designed questionnaire and structured interview were used to estimate extent and duration of improvement, as well as quality, distribution and duration of the side effects.
Results: The patients estimated that there was 68% of the improvement when compared before the onset of A/Abo. The effects of the therapy started at average 7 days after the application, and remained satisfactory significantly longer in HFS than CD (3.18±0.54 vs. 2.67±1.06 months). Total of 45% experienced at least one side effect during the course of the treatment, more often in HFS than CD (63% vs. 32%). Since last application side effects occurred in 19%, again more often in HSF, but did not reach statistical significance (28% vs. 14%). They occurred 4 days after the application of A/Abo, and lasted one month. The most frequent were facial palsy (6%), ptosis (4.5%) and pain at the injection site.
Conclusions: A/Abo is an efficient therapy for CD and HFS. Therapeutical effects, which are seen in 70% of the patients, start one week after the application of the drug and last longer in HFS. On the other hand, side effects occur less frequently in CD, both after a single dose and during the course of the treatment. They may be expected around 4 days after the application, usually are local and transient.
To cite this abstract in AMA style:
A. Jesic, D. Stefanovic, N. Delibasic, J. Radanov, M. Cvijanovic. Efficacy and safety of abobotulinumtoxinA in craniocervical dystonia and hemifacial spasm [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/efficacy-and-safety-of-abobotulinumtoxina-in-craniocervical-dystonia-and-hemifacial-spasm/. Accessed May 13, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/efficacy-and-safety-of-abobotulinumtoxina-in-craniocervical-dystonia-and-hemifacial-spasm/